13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • (AMG 404) 20180143

    Acronym: 

    AMG 404

    ACTRN/NCT /ethics: 

    NCT03853109

    Scientific title: 

    AMG 404 in Patients With Advanced Solid Tumors.

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream Solid tumours
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2019-03-05
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid tumours
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2019-03-05
    Anticipated End Date

    Trial Summary

    A phase I study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumours.

    Lay Summary

    AMG 404 in Patients With Advanced Solid Tumors.

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 Tim Price Recruiting